In Taiwan, one reason why Her-2-positive subtypes (Luminal B2 and Her-2-enriched) did not receive anti-Her2 target therapy could be that the National Health Insurance only approves this therapy in those with breast cancer with positive lymph node metastasis. This evidence concerns the gene ERBB2 and breast cancer.